Duloxetine
- Generic Name
- Duloxetine
- Brand Names
- Cymbalta, Drizalma, Irenka, Yentreve, Duloxetine Zentiva, Duloxetine Mylan, Duloxetine Lilly
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19NOS
- CAS Number
- 116539-59-4
- Unique Ingredient Identifier
- O5TNM5N07U
- Background
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the tre...
- Indication
Indicated for:
1) Management of Major Depressive Disorder.
2) Management of Generalized Anxiety Disorder.
3) Management of diabetic peripheral neuropathy.
4) Management of fibromyalgia.
5) Management of chronic musculoskeletal pain.
6) Management of osteoarthritis of the knee in adults.
7) Management of chronic lower back pain in adults.
...
- Associated Conditions
- Chronic Lower Back Pain (CLBP), Chronic Musculoskeletal Pain, Diabetic Peripheral Neuropathic Pain (DPN), Fibromyalgia, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Osteoarthritis of the Knee, Stress Urinary Incontinence (SUI)
- Associated Therapies
- -
Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 339
- Registration Number
- NCT02229825
Imaging Pain Relief in Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2014-08-05
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- University of Nottingham
- Target Recruit Count
- 77
- Registration Number
- NCT02208778
- Locations
- 🇬🇧
University of Nottingham - School of Medicine - Radiological Sciences, Nottingham, Nottinghamshire, United Kingdom
A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2022-02-18
- Target Recruit Count
- 56
- Registration Number
- NCT02174822
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Pain Prevention and Treatment Through the Enhancement of the Anti-nociceptive Component of Pain Modulation Profiles
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 5
- Registration Number
- NCT02020122
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
A Study of Duloxetine in Participants With Chronic Pain Due to Osteoarthritis in China
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 407
- Registration Number
- NCT01931475
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zhuzhou, China
An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 151
- Registration Number
- NCT01914666
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan
Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 82
- Registration Number
- NCT01912612
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
Interpersonal Psychotherapy for Treatment Resistant Depression
- Conditions
- Interventions
- Other: IPT+ antidepressant drugsDrug: fluoxetineDrug: sertralineDrug: paroxetineDrug: CitalopramDrug: escitalopramDrug: fluvoxamineDrug: VenlafaxineDrug: DuloxetineDrug: BupropionDrug: LithiumDrug: RisperidoneDrug: tranylcypromineDrug: ImipramineDrug: amitriptylineDrug: ClomipramineDrug: nortriptylineDrug: trazodoneDrug: MirtazapineDrug: sulpiride
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 74
- Registration Number
- NCT01896349
- Locations
- 🇧🇷
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
A Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 458
- Registration Number
- NCT01855919
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan
Duloxetine Treatment in Elderly With Dysthymia
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 30
- Registration Number
- NCT01852383
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.